Cidofovir inhalation - Nanotherapeutics

Drug Profile

Cidofovir inhalation - Nanotherapeutics

Latest Information Update: 26 Sep 2013

Price : $50

At a glance

  • Originator Nanotherapeutics
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 25 Feb 2012 No development reported - Preclinical for Smallpox in USA (Inhalation)
  • 25 Aug 2009 Preclinical trials in Smallpox in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top